Parabilis Medicines charts $413M IPO to back peptide pipeline

Mathai Mammen, Parabilis Medicines CEO (via Sandoz) June 4, 2026 09:04 AM EDT DealsIPOs Para­bilis Med­i­cines charts $413M IPO to back pep­tide pipeline Kyle LaHucik Biotech Correspondent Para­bilis Med­i­cines, the pep­tide biotech led by for­mer John­son & John­son R&D head Math­ai Mam­men, is seek­ing more than $400 mil­lion in its Nas­daq de­but. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER